Molecular Pharmacology (USA), Ltd. (MLPH)
Molecular Pharmacology (USA), Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Perth, WA, AU. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $643,711. On trailing twelve-month figures it carries a trailing P/E of -536.43, a net margin of 0.0%. Its beta of 0.17 implies it has historically moved less than the broad market.
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Molecular Pharmacology (USA), Ltd. is most often compared with the following Healthcare names: